Indian pharma market achieved lower growth of 7.2 per cent during the month of December 2016 as compared to 11.9 per cent in the corresponding period of last year. Market has added Rs.616 crore over last year, whereas last year the market had added up Rs.986 crore. According to AIOCD Pharmasofttech AWACS report the average growth for the quarter worked out to 10.3 per cent against 14.1 per cent in the last year. Chronic market moved up strongly at a double digit growth in November 2016 has come down to normal levels in December 2016. Anti-diabetic market grew at 16.2 per cent and cardiac market grew at 10.1 per cent. Without anti-diabetic & cardiac markets the IPM growth would have been 5.8 per cent. Indian companies have grown at 7.4 per cent versus 6.6 per cent for MNCs in December 2016.
During December 2016, GDs as 1.8 per cent in volumes, 2 per cent in price increases and 3.5 per cent in NIs. The volume growth was at 5.1 per cent and price growth the lowest in last six quarters at 1.9 per cent which has been consistently falling down on the back of price cuts. Price component in the GDs have been continuously going down from April 2016.
Chronic portfolio shows a high volume growth at 5.5 per cent against acute market volume growth of -1.5 per cent during December 2016. One more interesting factor to see is that the chronic volume growth of Nov-Dec 16 combined months is 10.5 per cent due to the high volume growths seen in November 2016.
The FDCs related market degrew at 30.4 per cent whereas the Non FDCs market grew at 8.4 per cent. From a GD perspective the FDC containing market showed a huge volume degrowth of -34.7 per cent. Indian companies grew by -33.8 per cent in the FDC portfolio whereas the MNCs grew by -22 per cent. For December 2016. There is a slight uptake on the portfolio which is under the FDCs with the market value of FDC at Rs.185 crore, which was Rs.176 crore in November 2016.
Abbott Laboratories and Intas registered growth of 12.2 per cent followed by Zydus at 11.9 per cent and Sun Pharma at 9.5 per cent. Among top 50 companies, 27 entities have crossed the growth of IPM for the months of December 2016 and Bharat Serums has the highest growth of 33.1 per cent followed by Boehringer Ingelheim at 27.3 per cent and J B Chemicals at 25.5 per cent. 21 companies showed growths of more than 10 per cent. Amongst the 11-20 ranked corporate, Emcure has the highest growth at 16.9 per cent followed by USV at 16.2 per cent & Torrent at 9.4 per cent.
Total 113 companies launched in last 36 months and 6 companies cross Rs.10 crore mark in revenue. The new companies launched within last 36 months is now being led by Saffron Therapeutics, Brinton Healthcare, Innovcare LifeSciences, Arinna Life Sciences & Jubilant Life Sciences.
Under the non-NLEM category Indian companies grew at -8.1 per cent whereas MNCs grew at -11.4 per cent. Amongst the top 50 in MNCs, Boehringer grew at 27.3 per cent followed by AstraZeneca at 15.0 per cent and Janssen at 12.6 per cent. The NLEM 2013 containing molecules market grew at -9.0 per cent whereas the non NLEM market grew by 9.8 per cent resulting in an overall growth of 7.2 per cent for December 2016. NLEM & non-NLEM category showed unit growth of 2.2 per cent and -0.8 per cent respectively.
From therapy perspective 12 therapies have outgrown the IPM growth. respiratory market grew at -0.9 per cent, gastro intestinal market grew at 7.5 per cent, pain & analgesics market grew at 3.2 per cent whereas anti-infectives grew at -4.8 per cent. Anti-diabetic market grows at 16.2 per cent & cardiac at 10.1 per cent, neuro/CNS at 5.0 per cent in chronic business. Anti-malarials degrew at 25.3 per cent, VMS market at 10.4 per cent. Derma market grew by 11.6 per cent & urology market at 11.0 per cent..
From regional perspective 15 regions have outgrown the IPM growth. Jharkhand market grew the highest at 26.9 per cent followed by Mumbai city market at 17.7 per cent & Karnataka market at 11.9 per cent. Three regions had negative growth in December 2016.
Amoxycillin+clavulanic acid market grew at -8.3 per cent & glimepiride+metformin market grew at 26.0 per cent. Glimepiride + metformin was pegged at Rs.165 crore & amoxycillin + clavulanic acid market pegged at Rs.143 crore in December 2016. Teneligliptin overall market is now worth Rs.334 crore in the entire gliptin market of Rs.2,208 crore and the SGLT2 market at Rs.195 crore on MAT basis.
The markets of paracetamol grew at 1.6 per cent, atorvastatin -10.8 per cent, probiotic microbes at 4.5 per cent, bacillus clausii market at 8.2 per cent, cefixime at -12.4 per cent, pantoprazole at 7.9 per cent, montelukast + levocetrizine at 10.9 per cent, glimepiride + metformin + pioglitazone at -17.3 per cent, vitamin-D at 6.2 per cent, hydroquinone + mometasone + tretinoin at -5.2 per cent, voglibose + metformin + glimepiride at 45.4 per cent, rosuvastatin at 19.6 per cent, protein supplements at 24.2 per cent, azithromycin at -17.0 per cent, calcium carbonate + vit D3 market at 17.0 per cent, paracetamol + phenylephrine + chlorpheniramine at 4.1 per cent, meropenem at 14.2 per cent and montelukast + fexofenadine at 11.7 per cent.
Mixtard from Novo Nordisk is the 1st brand in IPM to cross Rs.500 crore on MAT basis. Mixtard leads the pack with Rs. 43 crore followed by Spasmoproxyvon plus at Rs.37 crore, Glycomet GP at Rs.36 crore, Lantus Rs.29 crore, Galvus Met at Rs.28 crore and Augmentin at Rs.25 crore for December 2016.
Few Brands who have gained ranks include Hepcinat L (+33144), Hepcinat (+153), Cilacar (+58), Bortenat (+50), Duolin, Revital H (+44), Deriphyllin (+35), Zincovit, Udiliv, Ecosprin AV (+29), Zinetac, Chymoral Forte (+24), Novomix (+23), Duphaston (+22), Istamet (+19), Gluconorm G, Zoryl M (+18), Shelcal, Amaryl M (+17), Gemer, Huminsulin (+15), Rosuvas, Combiflam (+14), Vertin, Duphalac (+13), Allegra (+11), Ultracet, Pantop (+10), Synflorix, Levipil, Telma H, veenat (+9), Jalra M, Monocef O (+8), Pan (+7), Eltroxin, Aciloc RD (+6), Liv 52, Voveran, Betadine, Seroflo (+5) amongst top 100 Brands over December 2015.
New Launches in 2016 who have started showing big include Hepcinat LP, Panderm NM, Vivitra, Insta, Ondero Met, Terbinaforce Lite, Osteri, Sinarest New, Tendia M amongst others. Total 219 Brands & 454 SKUs launched in December 2016. Top 5 new brands for December 2016 are Flexon Plus, Vericare, Doloxicam, Nebzmart B, Dycerin OA. Zuventus enters the Sofosbuvir market by launching Zosovir in the Sofosbuvir market & Cimivir L by Biocon in the Sofosbuvir + Ledipasavir. Azilsartan is launched in December 2016 with 3 brands – Myotan (JBCPL), Arbazeal (Eris) & Azildac (Zydus). Biggest launch by MNCs – Rockbon PTH from Abbott.